Mark L. Ratner
By the end of July, Vanda Pharmaceuticals Inc. expects to know whether the US Food & Drug Administration will give the nod to its schizophrenia drug, iloperidone (Fiapta). The...
A handful of companies are pursuing predictive genetic tests for evaluating psychiatric drugs. The need is apparent, and an early success could trigger a rapid shift in thinking about the sustainability of building a business around biomarkers in a therapeutic area sometimes considered the least likely to benefit near term from their development. That said, firms in this area--and elsewhere--must be wary of leaning too heavily on pharma companies as supportive partners.
Mark L. Ratner
By the end of July, Vanda Pharmaceuticals Inc. expects to know whether the US Food & Drug Administration will give the nod to its schizophrenia drug, iloperidone (Fiapta). The...